Find all the latest information in myelodysplastic syndromes, arranged by subtypes and mutations.
How can we improve on current risk stratification in MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of...
What is the clinical impact of DDX41 mutations in myeloid neoplasms?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Yasushi Miyazaki, Nagasaki...
Results from the phase II P-2001 study on pevonedistat plus azacytidine for high-risk MDS
To further explore the clinical efficacy and safety of pevo in patients with high-risk MDS, CMML, or low-blast...
Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to...
TP53 allelic state has implications in MDS in terms of genomic stability, clinical presentation, and outcomes
Elsa Bernard and colleagues published in Nature Medicine in October 2020 how different...
The spectrum of clonal hematopoiesis
Clonal hematopoiesis (CH) describes the growth of a sub-population of blood cells that have at least one somatic mutation, leading to a greater risk of...
Tosedostat: A potential treatment option for MDS after hypomethylating agent failure
Here, we summarize the results of a phase II study (NCT02452346) investigating the safety and efficacy of...
Characterizing the genetic landscape of patients with myelodysplastic / myeloproliferative neoplasms
Making a differential diagnosis for subtypes of myelodysplastic/myeloproliferative neoplasms...
MDS precursor conditions
Clonal cytopenia of undetermined significance
Clonal hematopoiesis of indeterminate potential
BCR–ABL1-negative atypical chronic myeloid leukemia
Chronic myelomonocytic leukemia
MDS/MPN with ring sideroblasts and thrombocytosis
MDS with excess blasts
MDS with isolated del(5q)
MDS with multilineage dysplasia
MDS with ring sideroblasts
MDS with single-lineage dysplasia
Therapy-related myeloid neoplasms